Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11174132 | 0.85 | TDP1 (0.51) | TDP1SMN1; SMN2HTTLMNATBXAS1 | |
| SCHEMBL2332061 | 0.83 | TBXAS1 (0.52) | TDP1SMN1; SMN2HTTLMNAGAA | |
| SCHEMBL10460748 | 0.82 | CNR2 (0.57) | TDP1SMN1; SMN2HTTLMNAGAA | |
| SCHEMBL10452760 | 0.82 | CNR2 (0.54) | TDP1SMN1; SMN2HTTLMNAGAA | |
| SCHEMBL10461764 | 0.79 | CNR2 (0.53) | TDP1SMN1; SMN2HTTLMNATBXAS1 | |
| SCHEMBL10614317 | 0.77 | CA12 (0.58) | TDP1SMN1; SMN2HTTLMNAGAA | |
| SCHEMBL11170502 | 0.76 | KMT2A (0.44) | TDP1SMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL11576737 | 0.74 | CA12 (0.59) | TDP1SMN1; SMN2HTTLMNAGAA | |
| SCHEMBL11176553 | 0.74 | LMNA (0.45) | TDP1SMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL6949029 | 0.74 | PKLR (0.42) | TDP1SMN1; SMN2HTTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2374792-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | TDP1 1040/4885SMN1; SMN2 148/4885HTT 75/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | TDP1 1040/4885SMN1; SMN2 148/4885HTT 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.